Literature DB >> 2975218

Comparative in vitro activity of A-56268.

A M Sefton1, J P Maskell, F J Yong, S J Chi, J D Williams.   

Abstract

The comparative in vitro activity of A-56268 was studied using 1,006 clinical isolates including streptococci, enterococci, staphylococci, Neisseria gonorrhoeae, Haemophilus influenzae and anaerobes. A-56268 showed activity comparable to that of erythromycin and was more active than josamycin and roxithromycin against erythromycin-sensitive aerobic and facultatively anaerobic gram-positive cocci. A-56268 was the most active macrolide against Clostridium spp. and Neisseria gonorrhoeae. Josamycin was more active than either A-56268 or erythromycin against the anaerobic gram-positive cocci and the Bacteroides fragilis group. Staphylococci moderately resistant or resistant to erythromycin (MIC 3.12-50 mg/l) remained susceptible to josamycin but not the other macrolides.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2975218     DOI: 10.1007/bf01975054

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  11 in total

1.  The estimation of the bactericidal power of the blood.

Authors:  A A Miles; S S Misra; J O Irwin
Journal:  J Hyg (Lond)       Date:  1938-11

Review 2.  [Hepatitis caused by various derivatives of erythromycin].

Authors:  C Funck-Brentano; D Pessayre; J P Benhamou
Journal:  Gastroenterol Clin Biol       Date:  1983-04

3.  Gastrointestinal tract symptoms from intravenously administered erythromycin.

Authors:  L J Klika; J M Goodman
Journal:  JAMA       Date:  1982-09-17       Impact factor: 56.272

Review 4.  Comparative pharmacokinetics of macrolides.

Authors:  O G Nilsen
Journal:  J Antimicrob Chemother       Date:  1987-11       Impact factor: 5.790

5.  Clinical multicentre trial with josamycin propionate in paediatric patients.

Authors:  G Privitera; S Bonino; S Del Mastro
Journal:  Int J Clin Pharmacol Res       Date:  1984

6.  Comparison of the side effects and gastrointestinal motility observed after administration of erythromycin and josamycin to dogs.

Authors:  X Y Qin; M A Pilot; H H Thompson; J P Maskell
Journal:  J Antimicrob Chemother       Date:  1986-12       Impact factor: 5.790

7.  Comparative in vitro activity of A-56268 (TE-031), a new macrolide antibiotic.

Authors:  R L Hodinka; K Jack-Wait; P H Gilligan
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

8.  Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria.

Authors:  N X Chin; N M Neu; P Labthavikul; G Saha; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

9.  Erythromycin stearate, 1.5 g, for the oral prophylaxis of streptococcal bacteraemia in patients undergoing dental extraction: efficacy and tolerance.

Authors:  D C Shanson; S Akash; M Harris; M Tadayon
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

10.  In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide.

Authors:  P B Fernandes; R Bailer; R Swanson; C W Hanson; E McDonald; N Ramer; D Hardy; N Shipkowitz; R R Bower; E Gade
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

View more
  5 in total

1.  Absolute bioavailability of clarithromycin after oral administration in humans.

Authors:  S Y Chu; R Deaton; J Cavanaugh
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

Review 2.  Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections.

Authors:  C J Dunn; L B Barradell
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

Review 3.  Clarithromycin clinical pharmacokinetics.

Authors:  F Fraschini; F Scaglione; G Demartini
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

4.  Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses.

Authors:  S Y Chu; L T Sennello; S T Bunnell; L L Varga; D S Wilson; R C Sonders
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

Review 5.  Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use.

Authors:  A Markham; D Faulds
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.